News

Ultragenyx Pharmaceutical Inc. a biopharmaceutical company focused on the development of novel productsfor rare and ultra-rare genetic diseases, and Takeda Pharmaceutical Company Limited announced a strategic partnership to develop and commercialize therapies to treat rare genetic diseases. ...

In ENESTfreedom, 51.6% of eligible first-line Tasigna patients maintained TFR for 48 weeks after stopping treatment; study did not meet its statistical primary endpoint, specifically the > 50% lower limit of the 95% confidence interval ENESTop...

AbbVie GK announced that EA Pharma and AbbVie will commence the co-promotion of fully human anti-TNF-α monoclonal antibody HUMIRA® for indications in the field of gastrointestinal disease. Established in April 2016 through the integration of Eisai's...

GlaxoSmithKline plc and Innoviva, Inc announced that, following discussions with the US FDA ,GSK has brought forward the plan to file a NDA in the US for the once-daily closed triple combination therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; a combination inhaled...

AbbVie a global biopharmaceutical company announced that data on HUMIRA® (adalimumab), investigational medicines and research, including real-world evidence, aiming to improve clinical outcomes for patients with rheumatologic diseases, will be presented at the Annual European Congress of Rheumatology (EULAR...

PAREXEL International Corporation ,a leading global biopharmaceutical services provider, has been named Company of the Year – Pharmaceuticals in the 14th Annual American Business AwardsSM. The judges awarded PAREXEL a Gold Stevie® Award and recognized the...

Biogen announced that aducanumab, its investigational treatment for early Alzheimer’s disease (AD), was accepted into the European Medicines Agency’s (EMA) Priority Medicines (PRIME) program. PRIME aims to bring treatments to patients faster by enhancing the EMA’s support for the...